Edwards Lifesciences Corp
Close on Nov 19, 2026Market cap $59.88BP/E 59.7Yield –
Edwards Lifesciences Accrued Clinical Trial & Research and Development by Quarter
Accrued Clinical Trial & Research and Development Liabilities ($M)
Edwards Lifesciences Accrued Clinical Trial & Research and Development: $69.1M in Q3 2026, down 8.2% from a year earlier.
Where the Q3 2026 figure comes from
Source: SEC Filing (0001099800-26-000054) ↗
Reported in Form 10-K / Form 10-Q Balance Sheet & Accrued Liabilities Footnotes.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up accrued Clinical Trial & Research and Development
- Accrued Customer Rebates, Product Returns and Sales Allowances185 · Q3 2026
- Accrued Litigation & Insurance Reserves (Current)37.1 · Q3 2026
- Allowance for Credit Losses (Doubtful Accounts Receivable)17 · Q3 2026
- Total Litigation & IP Agreement Reserves (Current & Noncurrent)21.3 · Q3 2026
- Intellectual Property Litigation & Settlement Expenses, Net-12.7 · Q3 2026
Cite this data
StockData. (2026). Edwards Lifesciences Accrued Clinical Trial & Research and Development ($M), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Edwards Lifesciences SEC filings and investor materials. https://stockdatahq.com/stocks/ew/kpis/res-rd
See every metric in the Edwards Lifesciences KPI table. Data updated Nov 7, 2026.
See a number that looks wrong?